세계의 전장 유전체 및 엑솜 시퀀싱 시장 : 용도별, 생물별, 제품별, 전장 유전체 및 엑솜별 - 경영진 컨설턴트 가이드 포함, D2C 분석과 인공지능(AI)의 영향(2025-2029년)

OVERVIEW:

Will all newborns receive Whole Genome Sequencing at birth? How fast will Direct to Consumer Testing grow? What sequencing technology will take the lead? What's holding the industry back? Where are over 800 locations that have high throughput devices?

Our facts and support = Your success.

New consumers, new technologies, new specializations. In a situation reminiscent of the birth of the internet industry a wide range of well funded players are racing for market share on a truly global stage. The report forecasts the market size out five years. The report includes detailed breakouts for 14 countries and 5 regions.

Tumor Cell Sequencing? Direct to Consumer? Gene Expression? Find out about the technology in readily understood terms that explain the jargon. What are the issues? Find the opportunities, and the pitfalls. Understand growth expectations and the ultimate market forecasts for the next five years.

All report data is available in Excel format on request. Make investment decisions and valuations with confidence using the latest data.

Table of Contents

1. Market Guides

• 1.1. Whole Genome Sequencing Market - Strategic Situation Analysis
• 1.2. Guide for Executives, Marketing, Sales and Business Development Staff
• 1.3. Guide for Management Consultants and Investment Advisors
• 1.4. Impact of Artificial Intelligence on WGS

2. Introduction and Market Definition

• 2.1. Whole Genome Sequencing Definition In This Report
  • 2.1.1. Whole and Exome Sequencing
  • 2.1.2. Research
  • 2.1.3. Clinical Human
  • 2.1.4. Clinical Human Rapid
  • 2.1.5. Clinical Tumor
  • 2.1.6. Clinical Pathogen
  • 2.1.7. Agri/Other
  • 2.1.8. Direct to Consumer
• 2.2. The Genomics Revolution
• 2.3. Market Definition
  • 2.3.1. Revenue Market Size
• 2.4. Methodology
  • 2.4.1. Methodology
  • 2.4.2. Sources
  • 2.4.3. Authors
• 2.5. Perspective: Healthcare and the IVD Industry
  • 2.5.1. Global Healthcare Spending
  • 2.5.2. Spending on Diagnostics
  • 2.5.3. Important Role of Insurance for Diagnostics
• 2.6. Sizing the Genome - Not What You Think
  • 2.6.1. Cost, Price and Genome Size, Pricing Practice
• 2.7. GLOBAL LISTING OF HIGH THROUGHPUT SEQUENCING ESTABLISHMENTS INSTALLED BASE - Location & Contacts

3. Market Overview

• 3.1. Market Participants Play Different Roles
  • 3.1.1. Instrument Manufacturer
  • 3.1.2. Independent lab specialized/esoteric
  • 3.1.3. Independent lab national/regional
  • 3.1.4. Independent lab analytical
  • 3.1.5. Public National/regional lab
  • 3.1.6. Hospital lab
  • 3.1.7. Physician lab
  • 3.1.8. DTC Lab
  • 3.1.9. Sequencing Labs
  • 3.1.10. Audit body
• 3.2. Whole Genome Sequencing -Markets, Examples and Discussion
  • 3.2.1. Direct to Consumer - Two Approaches
    • 3.2.1.1. The New Age of Medical Information
    • 3.2.1.2. Dangers in DTC-WGS - Health Costs and Regulation
    • 3.2.1.3. Newborn and Prenatal - A Brave New World
    • 3.2.1.4. DTC - How Many Segments?
  • 3.2.2. Research Markets
    • 3.2.2.1. Research Funding and Capital Expense
    • 3.2.2.2. WGS Datasets Preferred
    • 3.2.2.3. Existing research repurposed
    • 3.2.2.4. Organism Wide Market
    • 3.2.2.5. Service Suppliers Respond
  • 3.2.3. Clinical - Understanding Germline and Somatic
    • 3.2.3.1. Somatic - Chasing Mutations and Pharmacogenomics
  • 3.2.4. Pathogen Testing
    • 3.2.4.1. The Hepatitis C Story
    • 3.2.4.2. Will theMicrobiology Department Disappear?
  • 3.2.5. AgriBio - Big Business
    • 3.2.5.1. GMO is Here to Stay
    • 3.2.5.2. WGS Benefits and Risks
    • 3.2.5.3. The New Agriculture
• 3.3. Industry Structure
  • 3.3.1. Hospital's Testing Share
  • 3.3.2. Economies of Scale
  • 3.3.3. Instrument Manufacturer Role
  • 3.3.4. Healthcare Industry Impacts - Still Struggling
    • 3.3.4.1. Can the Healthcare Industry Adapt?
    • 3.3.4.2. Genetic Counselling as an Industry
    • 3.3.4.3. WGES Adoption and Cannibalization
    • 3.3.4.4. The Meaning of Grail

4. Market Trends

• 4.1. Factors Driving Growth
  • 4.1.1. Diagnostic Factors
  • 4.1.2. Interpreting the Code Otherwise
  • 4.1.3. Changes in Agriculture
  • 4.1.4. Fertility Technology Comes of Age
  • 4.1.5. Pathogen Challenges
• 4.2. Factors Limiting Growth
  • 4.2.1. Increased Competition Lowers Price
  • 4.2.2. Lower Costs
  • 4.2.3. Healthcare Cost Concerns Curtail Growth
  • 4.2.4. Wellness has a downside
  • 4.2.5. GMO Opposition Movement
• 4.3. Sequencing Instrumentation
  • 4.3.1. Instrumentation Tenacity
  • 4.3.2. Declining Cost Changes Industry Structure
  • 4.3.3. LISTING of CURRENT NGS INSTRUMENT SPECIFICATIONS
  • 4.3.4. Illumina
  • 4.3.5. ION
  • 4.3.6. Pacific Biosystems
  • 4.3.7. Roche 454
  • 4.3.8. SOLiD
  • 4.3.9. Oxford Nanopore
    • 4.3.9.1. What is Oxford Nanopore Sequencing?
    • 4.3.9.2. What can Oxford Nanopore Sequencingt be used for?
    • 4.3.9.3. Oxford Nanopore Products
  • 4.3.10. Long Reads - Further Segmentation
  • 4.3.11. Linked Reads
  • 4.3.12. Targeted Sequencing Adopts CRISPR
  • 4.3.13. New Sequencing Technologies
    • 4.3.13.1. RNAP sequencing
    • 4.3.13.2. In vitro virus high-throughput sequencing
    • 4.3.13.3. Tunnelling currents DNA sequencing
    • 4.3.13.4. Sequencing by hybridization
    • 4.3.13.5. Sequencing with mass spectrometry
    • 4.3.13.6. Microfluidic Sanger sequencing
    • 4.3.13.7. Microscopy-based techniques

5. WGES Recent Developments

• 5.1. Recent Developments - Importance and How to Use This Section
  • 5.1.1. Importance of These Developments
  • 5.1.2. How to Use This Section
• 5.2. GeneDx to Acquire Fabric Genomics
• 5.3. WGS provides faster detection of Salmonella
• 5.4. UltraRapid WGS, Results in 48 Hours
• 5.5. WGS Identifies Desirable Tobacco Genes
• 5.6. The Case for WGS use in All Blood Cancers
• 5.7. $400 Personal WGS
• 5.8. Incorporating WGS into Cancer Care
• 5.9. Epic, GeneDx to broaden WGS potential
• 5.10. Qiagen QiaSeq xHyb Mycobacterium Tuberculosis Panel
• 5.11. WGS Uncovers Genetic causes of cerebral palsy
• 5.12. Rapid WGS Use recommended for Intensive Care
• 5.13. Quest and Ultima Genomics to Develop Tests
• 5.14. WHO launches WGS Guide
• 5.15. Myriad Genetics to Study MRD Testing
• 5.16. Adela Developing Epigenetic Multi-Cancer Detection
• 5.17. Epic Sciences Expanding Infrastructure for Liquid Biopsy Test
• 5.18. Bionano Laboratories Announces New Prenatal Whole Genome Tests
• 5.19. Myriad Genetics Plans Product Launches
• 5.20. Genomics England, Aims to Sequence 100K Newborns
• 5.21. Juno Diagnostics NIPT With At-Home Sample Collection
• 5.22. Cardio Diagnostics Launches Genetic Cardio Risk Test
• 5.23. Universal Genetic Testing in Breast Cancer Further Supported
• 5.24. Aniling Gets CE-IVD Marks for Cancer Sequencing Tests
• 5.25. MyOme Lands Investment for WGS
• 5.26. GenomSys Gains CE Mark for New Genomic Analysis Software
• 5.27. WGS Finds Lung Cancers Fall Into Molecular Subtypes
• 5.28. Testing Distinguishes Benign Tumors From Precancerous Condition
• 5.29. Plan to Sequence All Newborns in UK
• 5.30. Clear Labs Raises $60M for Nanopore Sequencing
• 5.31. Variantyx Expands Into Prenatal, Cancer Testing
• 5.32. Whole-Genome Sequencing Aids Diagnosis in Stockholm
• 5.33. Variantyx Raises $20M
• 5.34. Nonacus WGS Service for SARS-CoV-2 Laboratories
• 5.35. Center to Report Risk Scores in Clinical WGS
• 5.36. Stanford Launches WGS for Cardiovascular Testing
• 5.37. Illumina and NY Healthcare Partner on Clinical WGS
• 5.38. Increased Adoption of WGS Needs Acceptance by Payors, Providers
• 5.39. Veritas Intercontinental Completes Euro-5M Series B Financing Round
• 5.40. M2GEN and Discovery Life Sciences in Bioinformatics Agreement
• 5.41. Genomics England Adopts Quantum ActiveScale Object Storage
• 5.42. GenomiQa, Icon Group to Validate Genomic Analysis Platform CapeDx
• 5.43. NHS Wales Introduces WGS for Critically Ill Newborns
• 5.44. Illumina Achieves EAU for NGS-Based SARS-CoV-2 Test
• 5.45. C2i Genomics to Launch Trials for MRD Detection Tech
• 5.46. Roche Acquires Sequencing Company Stratos Genomics
• 5.47. UK COVID-19 Sequencing Consortium Launches
• 5.48. Invitae Acquires Three Companies: YouScript, Genelex, Diploid
• 5.49. Experience From Centralized Genomic Medicine Lab
• 5.50. MGI to Enable $100 Human Genome
• 5.51. Nebula Genomics offers $299 WGS
• 5.52. Team to Study Campylobacter Omics
• 5.53. Veritas Genetics Restarts US Business
• 5.54. NEOGEN, Gencove partner to advance animal genomics

6. Profiles of Key Companies

• 6.1. 10x Genomics, Inc.
• 6.2. 1928 Diagnostics
• 6.3. 23andME Inc.
• 6.4. Abbott Laboratories
• 6.5. AccuraGen Inc.
• 6.6. Adaptive Biotechnologies
• 6.7. Admera Health, LLC
• 6.8. Agilent/Dako
• 6.9. Akonni Biosystems
• 6.10. Amoy Diagnostics Co., Ltd.
• 6.11. Ancestry.com LLC
• 6.12. Anchor Dx
• 6.13. ARUP Laboratories
• 6.14. BaseClear
• 6.15. Baylor Miraca Genetics Laboratories
• 6.16. Beckman Coulter Diagnostics
• 6.17. Becton, Dickinson and Company
• 6.18. BGI Genomics Co. Ltd
• 6.19. Bioarray Genetics
• 6.20. Biocept, Inc.
• 6.21. Biodesix Inc.
• 6.22. BioFluidica
• 6.23. BioGenex
• 6.24. Biolidics Ltd
• 6.25. bioMerieux Diagnostics
• 6.26. Bioneer Corporation
• 6.27. Bio-Rad Laboratories, Inc
• 6.28. Bio-Techne
• 6.29. C2i Genomics
• 6.30. Caris Molecular Diagnostics
• 6.31. CellMax Life
• 6.32. Centogene
• 6.33. Circulogene
• 6.34. Clear Labs
• 6.35. Clinical Genomics
• 6.36. Complete Genomics, Inc. - A BGI Company
• 6.37. CosmosID
• 6.38. Dante Labs
• 6.39. Datar Cancer Genetics Limited
• 6.40. Day Zero Diagnostics.
• 6.41. Diasorin S.p.A.
• 6.42. Element Biosciences
• 6.43. Element Biosciences
• 6.44. Epic Sciences
• 6.45. Epigenomics AG
• 6.46. Eurofins Scientific
• 6.47. Excellerate Bioscience
• 6.48. Fabric Genomics
• 6.49. Freenome
• 6.50. FUJIFILM Wako Diagnostics
• 6.51. Fulgent Genetics
• 6.52. GE Global Research
• 6.53. Gencove
• 6.54. Genedrive
• 6.55. GeneDx Holdings
• 6.56. GeneFirst Ltd.
• 6.57. Genetron Holdings
• 6.58. Genewiz
• 6.59. Genomics England
• 6.60. Genomics Personalized Health (GPH)
• 6.61. GenomOncology
• 6.62. Genzyme Corporation
• 6.63. Grifols
• 6.64. Guardant Health
• 6.65. Guardiome
• 6.66. HeiScreen
• 6.67. Helix
• 6.68. Helix OpCo
• 6.69. Helomics
• 6.70. Hologic
• 6.71. HTG Molecular Diagnostics
• 6.72. Human Longevity, Inc.
• 6.73. iCellate
• 6.74. Illumina
• 6.75. Incell Dx
• 6.76. Inivata
• 6.77. Invitae Corporation
• 6.78. Invivoscribe
• 6.79. Karius
• 6.80. Lunglife AI Inc
• 6.81. Macrogen
• 6.82. MDNA Life SCIENCES, Inc.
• 6.83. MDx Health
• 6.84. Medgenome
• 6.85. Meridian Bioscience
• 6.86. Mesa Biotech (Thermo Fisher)
• 6.87. Mesa Laboratories, Inc.
• 6.88. miR Scientific
• 6.89. MNG Labs
• 6.90. NantHealth, Inc.
• 6.91. Natera
• 6.92. Nebula Genomics
• 6.93. NeoGenomics
• 6.94. New England Biolabs, Inc.
• 6.95. Novogene Bioinformatics Technology Co., Ltd.
• 6.96. Omega Bioservices
• 6.97. Oncocyte
• 6.98. OncoDNA
• 6.99. OpGen
• 6.100. ORIG3N, Inc.
• 6.101. Origene Technologies
• 6.102. Oxford Nanopore Technologies
• 6.103. Pacific Biosciences
• 6.104. Panagene
• 6.105. Pathogenomix
• 6.106. PathoQuest S.A.
• 6.107. Personal Genome Diagnostics
• 6.108. Personalis
• 6.109. Precipio
• 6.110. PrecisionMed
• 6.111. Promega
• 6.112. Protagen Diagnostics
• 6.113. Qiagen
• 6.114. QuantuMDx
• 6.115. Regeneron Pharmaceuticals
• 6.116. Revvity
• 6.117. Roche Molecular Diagnostics
• 6.118. Roswell Biotechnologies
• 6.119. Seegene
• 6.120. Sequencing.com
• 6.121. Siemens Healthineers
• 6.122. simfo GmbH
• 6.123. Singlera Genomics Inc.
• 6.124. Singular Genomics
• 6.125. SkylineDx
• 6.126. Standard BioTools
• 6.127. Sure Genomics, Inc.
• 6.128. Sysmex
• 6.129. Sysmex Inostics
• 6.130. Tempus Labs, Inc.
• 6.131. Thermo Fisher Scientific Inc.
• 6.132. Ultima Genomics
• 6.133. Ultima Genomics
• 6.134. Variantyx
• 6.135. Volition
• 6.136. Vyant Bio
• 6.137. Zymo Research Corp

7. The Global Market for Whole Genome Sequencing

• 7.1. Global Market Overview by Country
  • 7.1.1. Table - Global Market by Country
  • 7.1.2. Chart - Global Market by Country
• 7.2. Global Market by Application - Overview
  • 7.2.1. Table - Global Market by Application
  • 7.2.2. Chart - Global Market by Application - Base/Final Year Comparison
  • 7.2.3. Chart - Global Market by Application - Base Year
  • 7.2.4. Chart - Global Market by Application - Final Year
  • 7.2.5. Chart - Global Market by Application - Share by Year
  • 7.2.6. Chart - Global Market by Application - Segment Growth
• 7.3. Global Market by Organism - Overview
  • 7.3.1. Table - Global Market by Organism
  • 7.3.2. Chart - Global Market by Organism - Base/Final Year Comparison
  • 7.3.3. Chart - Global Market by Organism - Base Year
  • 7.3.4. Chart - Global Market by Organism - Final Year
  • 7.3.5. Chart - Global Market by Organism - Share by Year
  • 7.3.6. Chart - Global Market by Organism - Segment Growth
• 7.4. Global Market by Product - Overview
  • 7.4.1. Table - Global Market by Product
  • 7.4.2. Chart - Global Market by Product - Base/Final Year Comparison
  • 7.4.3. Chart - Global Market by Product - Base Year
  • 7.4.4. Chart - Global Market by Product - Final Year
  • 7.4.5. Chart - Global Market by Product - Share by Year
  • 7.4.6. Chart - Global Market by Product - Segment Growth
• 7.5. Global Market by Whole/Exome - Overview
  • 7.5.1. Table - Global Market by Whole/Exome
  • 7.5.2. Chart - Global Market by Whole/Exome - Base/Final Year Comparison
  • 7.5.3. Chart - Global Market by Whole/Exome - Base Year
  • 7.5.4. Chart - Global Market by Whole/Exome - Final Year
  • 7.5.5. Chart - Global Market by Whole/Exome - Share by Year
  • 7.5.6. Chart - Global Market by Whole/Exome - Segment Growth

8. Global Whole Genome Sequencing Markets - by Application

• 8.1. Research
  • 8.1.1. Table Research - by Country
  • 8.1.2. Chart - Research Growth
• 8.2. Clinical Human
  • 8.2.1. Table Clinical Human - by Country
  • 8.2.2. Chart - Clinical Human Growth
• 8.3. Clinical Human Rapid
  • 8.3.1. Table Clinical Human Rapid - by Country
  • 8.3.2. Chart - Clinical Human Rapid Growth
• 8.4. Clinical Tumor
  • 8.4.1. Table Clinical Tumor - by Country
  • 8.4.2. Chart - Clinical Tumor Growth
• 8.5. Clinical Pathogen
  • 8.5.1. Table Clinical Pathogen - by Country
  • 8.5.2. Chart - Clinical Pathogen Growth
• 8.6. Direct to Consumer
  • 8.6.1. Table Direct to Consumer - by Country
  • 8.6.2. Chart - Direct to Consumer Growth
• 8.7. Agriculture/Other
  • 8.7.1. Table Agriculture/Other - by Country
  • 8.7.2. Chart - Agriculture/Other Growth

9. Global Whole Genome Sequencing Markets - by Organism

• 9.1. Human
  • 9.1.1. Table Human - by Country
  • 9.1.2. Chart - Human Growth
• 9.2. Pathogen
  • 9.2.1. Table Pathogen - by Country
  • 9.2.2. Chart - Pathogen Growth
• 9.3. Other Organism
  • 9.3.1. Table Other Organism - by Country
  • 9.3.2. Chart - Other Organism Growth

10. Global Whole Genome Sequencing Markets - by Product

• 10.1. Instruments
  • 10.1.1. Table Instruments - by Country
  • 10.1.2. Chart - Instruments Growth
• 10.2. Reagents
  • 10.2.1. Table Reagents - by Country
  • 10.2.2. Chart - Reagent Growth
• 10.3. Analysis
  • 10.3.1. Table Analysis - by Country
  • 10.3.2. Chart - Analysis Growth
• 10.4. Software & Other
  • 10.4.1. Table Software & Other - by Country
  • 10.4.2. Chart - Software & Other Growth

11. Global Whole Genome Sequencing Markets - by Whole/Exome

• 11.1. Whole Genome
  • 11.1.1. Table Whole Genome - by Country
  • 11.1.2. Chart - Whole Genome Growth
• 11.2. Exome Only
  • 11.2.1. Table Exome Only - by Country
  • 11.2.2. Chart - Exome Only Growth
• 11.3. Other/Mix
  • 11.3.1. Table Other/Mix - by Country
  • 11.3.2. Chart - Other/Mix Growth

12. Vision of the Future of Whole Genome Sequencing

13. Appendices

• 13.1. United States Medicare System: Laboratory Fees Schedule
• 13.2. The Most Used IVD Assays
• 13.3. The Highest Grossing Assays
• 13.4. The Whole Genome Sequence of SARS-CoV-2